The process of eating, which releases nutrients, stimulates glucagon-like peptide-1, an appetite hormone we naturally have in our bodies, which decreases appetite and creates fullness
This variant is located in the GLP1R gene, which codes for the receptor protein that is the target of GLP-1 medications
Pharma companies are rapidly expanding and reprioritizing their research pipelines, with more than 135 GLP-1 candidates currently in various stages of development
Bottom line: if your week revolves around a GLP-1 dose, this is the tracker built around that week
As semaglutide suppresses appetite and delays gastric emptying, patients do not feel an urge to eat frequently, which helps with weight loss and weight management
These effects typically emerge within the first 1-2 weeks and often improve over 4-8 weeks as the body adapts